Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials

Correlations were interpreted as very weak (0.00-0.19), weak (0.20-0.39), moderate (0.40-0.59), or strong (0.60-0.79).10 RESULTS Baseline characteristics Baseline demographics, disease characteristics, and biomarkers (Supplementary Table 1) were balanced among treatment groups and were consistent with a population with severe CRSwNP. Further research is needed to determine which biomarkers of type 2 inflammation best correlate with disease-specific objective measures of severity and subjective patient-reported outcomes. [Extracted from the article]